United Kingdom -
English -
MHRA (Medicines & Healthcare Products Regulatory Agency)
avonex 30micrograms0.5ml (6million units) solution for injection pre-filled pen
6million units - interferon beta-1a - solution for injection - 12mega u/1ml
United Kingdom -
English -
MHRA (Medicines & Healthcare Products Regulatory Agency)
fampyra 10mg modified-release tablets
biogen idec ltd - fampridine - modified-release tablet - 10mg
United Kingdom -
English -
MHRA (Medicines & Healthcare Products Regulatory Agency)
tecfidera 120mg gastro-resistant capsules
biogen idec ltd - dimethyl fumarate - gastro-resistant capsule - 120mg
United Kingdom -
English -
MHRA (Medicines & Healthcare Products Regulatory Agency)
tecfidera 240mg gastro-resistant capsules
biogen idec ltd - dimethyl fumarate - gastro-resistant capsule - 240mg
United Kingdom -
English -
MHRA (Medicines & Healthcare Products Regulatory Agency)
plegridy 63micrograms0.5ml solution for injection pre-filled pen
biogen idec ltd - peginterferon beta-1a - solution for injection - 126microgram/1ml
United Kingdom -
English -
MHRA (Medicines & Healthcare Products Regulatory Agency)
plegridy 94micrograms0.5ml solution for injection pre-filled pen
biogen idec ltd - peginterferon beta-1a - solution for injection - 188microgram/1ml
United Kingdom -
English -
MHRA (Medicines & Healthcare Products Regulatory Agency)
plegridy 125micrograms0.5ml solution for injection pre-filled pen
biogen idec ltd - peginterferon beta-1a - solution for injection - 250microgram/1ml
United Kingdom -
English -
MHRA (Medicines & Healthcare Products Regulatory Agency)
spinraza 12mg5ml solution for injection vials
biogen idec ltd - nusinersen sodium - solution for injection - 2.4mg/1ml
European Union -
English -
EMA (European Medicines Agency)
vumerity
biogen netherlands b.v. - diroximel fumarate (biib098) - multiple sclerosis, relapsing-remitting - immunosuppressants - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5.1 for important information on the populations for which efficacy has been established).